Guardant Health Announces Proposed Public Offering of Common Stock
22 Maio 2023 - 5:23PM
Business Wire
Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology
company, today announced that it has commenced an underwritten
public offering of $250.0 million of its common stock. In addition,
Guardant Health intends to grant the underwriters a 30-day option
to purchase up to $37.5 million of its common stock at the public
offering price, less underwriting discounts and commissions. All of
the shares of common stock in this offering will be sold by
Guardant Health. The proposed offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the proposed offering may be completed, or as to the actual
size or terms of the proposed offering.
J.P. Morgan, Goldman Sachs & Co. LLC, TD Cowen and SVB
Securities are acting as joint book-running managers for the
proposed offering.
The shares of common stock are being offered by Guardant Health
pursuant to an automatic shelf registration statement on Form S-3
that was previously filed with the U.S. Securities and Exchange
Commission, or the SEC, and automatically became effective upon
filing. A preliminary prospectus supplement and accompanying
prospectus relating to and describing the terms of the proposed
offering has been filed with the SEC and is available on the SEC’s
website at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus may be obtained by contacting:
J.P. Morgan Securities LLC c/o Broadridge Financial Solutions
1155 Long Island Avenue, Edgewood, NY 11717 Telephone: (866)
803-9204, or email: prospectus-eq_fi@jpmorganchase.com;
Goldman Sachs & Co. LLC Attention: Prospectus Department 200
West Street, New York, NY 10282 Telephone: (866) 471-2526, or
email: prospectus-ny@ny.email.gs.com;
Cowen and Company, LLC 599 Lexington Avenue, New York, NY 10022
Telephone: (833) 297-2926, or email: Prospectus_ECM@cowen.com;
SVB Securities LLC Attention: Syndicate Department 53 State
Street, 40th Floor, Boston, MA 02109 Telephone: (800) 808-7525,
ext. 6105, or email: syndicate@svbsecurities.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY™ tests for advanced-stage cancer, and Guardant
Reveal™ for early-stage cancer. The Guardant Health screening
portfolio, including the commercially launched Shield™ test, aims
to address the needs of individuals eligible for cancer
screening.
Forward Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation statements regarding the
completion, timing and size of the proposed public offering and the
grant to the underwriters of an option to purchase additional
shares are forward-looking statements reflecting the current
beliefs and expectations of Guardant Health’s management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements represent
Guardant Health’s current expectations regarding future events and
are subject to known and unknown risks and uncertainties that could
cause actual results to differ materially from those implied by the
forward-looking statements. Among those risks and uncertainties are
market conditions, including market interest rates, the trading
price and volatility of Guardant Health’s common stock, and risks
relating to Guardant Health’s business, including those risks
described in periodic reports that Guardant Health files from time
to time with the SEC, as well as the preliminary prospectus
supplement and accompanying prospectus relating to the proposed
offering. The forward-looking statements included in this press
release speak only as of the date of this press release, and
Guardant Health does not undertake to update the statements
included in this press release for subsequent developments, except
as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230522005700/en/
Investor Contact: investors@guardanthealth.com
Media Contact: press@guardanthealth.com
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024